Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
57
datasets available to search
ShareScore release 0.9.0
Dataset results
57 results for “Precision Oncology”
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
ClinicalTrials.gov study NCT05906407. IPD Sharing: NO. Countries: 1. Publications: 0.
PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc
ClinicalTrials.gov study NCT04814095. IPD Sharing: NO. Countries: 1. Publications: 0.
Precise Oncology Interventions in Nutrition and Training (OnPoint)
ClinicalTrials.gov study NCT06534918. IPD Sharing: NO. Countries: 1. Publications: 0.
Functional Precision Oncology for Metastatic Breast Cancer
ClinicalTrials.gov study NCT04450706. IPD Sharing: NO. Countries: 1. Publications: 0.
Development of a Platform for the Clinical Implementation of Precision Oncology in the Central-Southern Regions of Italy (COESIT)
ClinicalTrials.gov study NCT06894823. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors
ClinicalTrials.gov study NCT04110223. IPD Sharing: NO. Countries: 1. Publications: 0.
The ACC Preclinical Research Platform for Precision Oncology
ClinicalTrials.gov study NCT06339541. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Towards Optimization of Precision Oncology in Metastatic Uterine Tumors
GEO Series GSE216313. Homo sapiens. 15 samples. Type: Methylation profiling by genome tiling array.
Towards Optimization of Precision Oncology in Metastatic Uterine Tumors
GEO Series GSE214779. Homo sapiens. 13 samples. Type: Expression profiling by high throughput sequencing.
SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3-BASED GLIOMA PATIENT STRATIFICATION AND APPLICATION IN PRECISION ONCOLOGY
GEO Series GSE117905. Homo sapiens. 16 samples. Type: Expression profiling by array.
The OncoLoop Network-based Precision Oncology Framework
GEO Series GSE186566. Mus musculus. 112 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "The Complementary Role of PSMA Expression and [18F]FDG PET/CT in Predicting Thyroid Cancer Outcome - from Black and White to Shades of Gray, in the Era of Precision Oncology"
<p>This record contains data related to article "<strong>The Complementary Role of PSMA Expression and [<sup>18</sup>F]FDG PET/CT in Predicting Thyroid Cancer Outcome - from Black and White to Shades of Gray, in the Era of Precision Oncology</strong>"</p> <p>Abstract<br> Background The value of Prostate Specific Membrane Antigen (PSMA) in thyroid carcinoma (TC) is still unknown. We<br> aimed to test the potential complementary role of PSMA expression and 2-[18F]fluoro-2-deoxy-D-glucose ([<br> 18F]FDG)<br> uptake on PET/CT as biomarkers for TC outcome prediction.<br> Materials and methods From a retrospective cohort of TC patients we selected those fulfilling the following inclusion/<br> exclusion criteria: thyroidectomy in our Institution, available primary tumor tissue PSMA immunostaining, [<br> 18F]<br> FDG PET/CT and follow-up data. PSMA staining was visually assessed. PET/CT was considered positive in case of [<br> 18F]<br> FDG uptake higher than the background at the site of TC confirmed by cyto-/histology, and/or follow-up. Disease<br> recurrence, radioiodine refractoriness (RAI-R) and status at last follow-up (LFU) were used as outcome endpoints.<br> Results We included 23 subjects. Disease recurrence occurred in 18 patients (median time 11 months, range 1–40);<br> among these 12/18 developed RAI-R (median time 28 months, range 2–221), and 13/18 had evidence of disease at<br> LFU. PSMA expression was negative in 6/23 cases. PET/CT was negative in 11/23 patients (7/11 experienced recurrence).<br> PET/CT was positive in 9/12 patients showing RAI-R and 10/13 cases with evidence of disease at LFU. All<br> patients with positive PET/CT had a positive PSMA immunostaining. Six out of 11 patients with negative PET/CT were<br> positive at immunostaining, showing lower PSMA expression (median score of 30%, range 0–80%) than patients with<br> positive PET/CT. The TC samples without PSMA expression belonged to patients who resulted negative also at PET/CT<br> (3 experienced recurrence, 2 were RAI-R, and 1 had disease at LFU). Four out of 11 patients who resulted negative at<br> PET/CT exhibited very high PSMA expression (≥ 70%) and although 3 of them experienced recurrence, none resulted<br> RAI-R, and only 1 had persistent disease at LFU.<br> Conclusions Primary tumor PSMA expression and [<br> 18F]FDG uptake seem to play a complementary prognostic role in<br> TC. The majority of patients who expressed PSMA recurred. In the intermediate ATA risk class, patients with negative<br> PSMA immunostaining recurred less than patients expressing PSMA. Additionally, although patients with a negative</p>
Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma
GEO Series GSE84323. Homo sapiens. 152 samples. Type: Expression profiling by high throughput sequencing.
Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments
GEO Series GSE197763. Homo sapiens. 126 samples. Type: Expression profiling by high throughput sequencing.
An RNA-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
GEO Series GSE212854. Homo sapiens. 25 samples. Type: Expression profiling by high throughput sequencing.
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
INFORM is a prospective, multinational registry gathering clinical and molecular data of relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long-term follow-up of 519 patients in whom molecular alterations were evaluated according to a predefined seven-scale target prioritization algorithm.
Implementation of pediatric precision oncology into clinical practice: The individualized Therapies for Children with cancer program "iTHER"
<p>Published in: European Journal of Cancer</p> <p>https://doi.org/10.1016/j.ejca.2022.09.001</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.